|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,860.00 KRW | +0.21% |
|
-8.82% | -28.74% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 25-06-12 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Profitability | |||||||
Return on Assets | -3.13 | -4.43 | 0.22 | -1.85 | 1.23 | ||
Return on Total Capital | -4.11 | -5.76 | 0.27 | -2.07 | 1.29 | ||
Return On Equity % | 1.56 | -16.52 | -2.13 | -4.32 | 7.26 | ||
Return on Common Equity | 1.56 | -16.52 | -2.13 | -4.32 | 7.26 | ||
Margin Analysis | |||||||
Gross Profit Margin % | 38.81 | 44.64 | 50.19 | 45.22 | 46.39 | ||
SG&A Margin | 22.73 | 23.07 | 21.22 | 24.97 | 20.34 | ||
EBITDA Margin % | -0.28 | -1.78 | 13.56 | 7.67 | 13.01 | ||
EBITA Margin % | -10.99 | -13.07 | 0.92 | -4.4 | 4.24 | ||
EBIT Margin % | -11.4 | -13.42 | 0.59 | -4.76 | 3.92 | ||
Income From Continuing Operations Margin % | 1.58 | -15.61 | -2.02 | -4.86 | 12.83 | ||
Net Income Margin % | 1.58 | -15.61 | -2.02 | -4.86 | 12.83 | ||
Net Avail. For Common Margin % | 1.58 | -15.61 | -2.02 | -4.86 | 12.83 | ||
Normalized Net Income Margin | 1.42 | -9.92 | -1.87 | -0.01 | 4.87 | ||
Levered Free Cash Flow Margin | -20.79 | -3.87 | -27.83 | -11.59 | -3.35 | ||
Unlevered Free Cash Flow Margin | -15.78 | 0.52 | -25.72 | -9.28 | -2.95 | ||
Asset Turnover | |||||||
Asset Turnover | 0.44 | 0.53 | 0.6 | 0.62 | 0.5 | ||
Fixed Assets Turnover | 2.48 | 1.83 | 1.48 | 1.54 | 2.32 | ||
Receivables Turnover (Average Receivables) | 6.97 | 6.09 | 6.4 | 5.31 | 5.07 | ||
Inventory Turnover (Average Inventory) | - | 14.85 | 11.56 | 11.96 | 10.51 | ||
Short Term Liquidity | |||||||
Current Ratio | 6.42 | 2.32 | 1.12 | 4.27 | 18.59 | ||
Quick Ratio | 6.26 | 2.13 | 1 | 3.74 | 17.67 | ||
Operating Cash Flow to Current Liabilities | -0.01 | -0.15 | 0.26 | 0.12 | 0.47 | ||
Days Sales Outstanding (Average Receivables) | 52.36 | 59.97 | 57.02 | 68.89 | 71.97 | ||
Days Outstanding Inventory (Average Inventory) | - | 24.58 | 31.57 | 30.6 | 34.72 | ||
Average Days Payable Outstanding | - | 34.08 | 29.14 | - | - | ||
Cash Conversion Cycle (Average Days) | - | 50.47 | 59.46 | - | - | ||
Long Term Solvency | |||||||
Total Debt/Equity | 74.37 | 39.89 | 46.94 | 14.12 | 5.13 | ||
Total Debt / Total Capital | 42.65 | 28.51 | 31.94 | 12.37 | 4.88 | ||
LT Debt/Equity | 70.76 | 36.14 | 17.56 | 11.72 | 4.07 | ||
Long-Term Debt / Total Capital | 40.58 | 25.83 | 11.95 | 10.27 | 3.87 | ||
Total Liabilities / Total Assets | 55.3 | 45.63 | 41.5 | 18.57 | 7.51 | ||
EBIT / Interest Expense | -1.42 | -1.91 | 0.17 | -1.29 | 6.27 | ||
EBITDA / Interest Expense | -0.04 | -0.25 | 4.02 | 2.07 | 20.81 | ||
(EBITDA - Capex) / Interest Expense | -1.97 | -2.63 | -4.02 | 1.73 | 19.23 | ||
Total Debt / EBITDA | -271.85 | -24.72 | 3.18 | 2.35 | 0.98 | ||
Net Debt / EBITDA | 224.25 | 16.39 | 0.84 | -0.94 | -8.8 | ||
Total Debt / (EBITDA - Capex) | -4.83 | -2.38 | -3.17 | 2.82 | 1.06 | ||
Net Debt / (EBITDA - Capex) | 3.99 | 1.58 | -0.84 | -1.12 | -9.52 | ||
Growth Over Prior Year | |||||||
Total Revenues, 1 Yr. Growth % | 36.46 | 30.36 | 13.18 | -5.15 | 21.81 | ||
Gross Profit, 1 Yr. Growth % | 17.72 | 49.93 | 27.24 | -14.53 | 24.96 | ||
EBITDA, 1 Yr. Growth % | -105.3 | 726.74 | -962.65 | -46.34 | 106.58 | ||
EBITA, 1 Yr. Growth % | -3.7K | 55.05 | -107.94 | -555.37 | -217.45 | ||
EBIT, 1 Yr. Growth % | 77.25K | 53.42 | -104.95 | -870.57 | -200.17 | ||
Earnings From Cont. Operations, 1 Yr. Growth % | -11.07K | -1.38K | -85.38 | 128.49 | -421.77 | ||
Net Income, 1 Yr. Growth % | -11.07K | -1.38K | -85.38 | 128.49 | -421.77 | ||
Normalized Net Income, 1 Yr. Growth % | -1.23K | -1.01K | -78.67 | -99.61 | -77.06K | ||
Diluted EPS Before Extra, 1 Yr. Growth % | -12.32K | -1.37K | -87.12 | 130 | -367.5 | ||
Accounts Receivable, 1 Yr. Growth % | 130.77 | 14.01 | 2.03 | 26.29 | 28.64 | ||
Inventory, 1 Yr. Growth % | - | 100.57 | -3.97 | 5.78 | 63.88 | ||
Net Property, Plant and Equip., 1 Yr. Growth % | 24.85 | 118.2 | 3.67 | -20.47 | -17.86 | ||
Total Assets, 1 Yr. Growth % | 1.39 | 15.24 | -12.43 | -5.13 | 108.32 | ||
Tangible Book Value, 1 Yr. Growth % | 1.69 | 41.74 | -5.74 | 32.79 | 138.82 | ||
Common Equity, 1 Yr. Growth % | 1.69 | 40.17 | -5.78 | 32.07 | 136.62 | ||
Cash From Operations, 1 Yr. Growth % | -110.12 | 2.28K | -307.42 | -88.68 | 243.12 | ||
Capital Expenditures, 1 Yr. Growth % | 18.68 | 40.49 | 83.82 | -95.56 | -5.24 | ||
Levered Free Cash Flow, 1 Yr. Growth % | 62.31 | -75.73 | 713.88 | -60.49 | -64.85 | ||
Unlevered Free Cash Flow, 1 Yr. Growth % | 27.24 | -104.33 | -5.66K | -65.8 | -61.2 | ||
Compound Annual Growth Rate Over Two Years | |||||||
Total Revenues, 2 Yr. CAGR % | 23.36 | 33.37 | 21.47 | 3.61 | 7.49 | ||
Gross Profit, 2 Yr. CAGR % | 16.86 | 32.85 | 38.12 | 4.28 | 3.34 | ||
EBITDA, 2 Yr. CAGR % | -78.61 | -33.78 | 744.5 | 115.16 | 5.29 | ||
EBITA, 2 Yr. CAGR % | 125.83 | 646.99 | -64.92 | -39.88 | 131.26 | ||
EBIT, 2 Yr. CAGR % | 144.28 | 3.34K | -72.45 | -38.26 | 177.83 | ||
Earnings From Cont. Operations, 2 Yr. CAGR % | 12.07 | 3.65K | 36.97 | -42.21 | 171.15 | ||
Net Income, 2 Yr. CAGR % | 12.07 | 3.65K | 36.97 | -42.21 | 171.15 | ||
Normalized Net Income, 2 Yr. CAGR % | 19.06 | 914.33 | 39.33 | -97.11 | 73.6 | ||
Diluted EPS Before Extra, 2 Yr. CAGR % | -14.37 | 3.84K | 27.93 | -45.58 | 148.04 | ||
Accounts Receivable, 2 Yr. CAGR % | 67.67 | 62.2 | 7.85 | 13.51 | 27.46 | ||
Inventory, 2 Yr. CAGR % | - | - | 38.78 | 0.79 | 31.67 | ||
Net Property, Plant and Equip., 2 Yr. CAGR % | 30.91 | 65.05 | 50.4 | -9.2 | -19.18 | ||
Total Assets, 2 Yr. CAGR % | 74.03 | 8.09 | 0.46 | -8.85 | 40.58 | ||
Tangible Book Value, 2 Yr. CAGR % | 49.72 | 20.06 | 15.59 | 11.88 | 78.08 | ||
Common Equity, 2 Yr. CAGR % | 48.34 | 19.39 | 14.92 | 11.55 | 76.77 | ||
Cash From Operations, 2 Yr. CAGR % | -72.5 | 55.16 | 602.43 | -51.55 | -37.69 | ||
Capital Expenditures, 2 Yr. CAGR % | 46.81 | 29.13 | 60.7 | -71.44 | -79.49 | ||
Levered Free Cash Flow, 2 Yr. CAGR % | - | -37.24 | 40.54 | 79.32 | -62.73 | ||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | -76.53 | 55.07 | 335.94 | -63.57 | ||
Compound Annual Growth Rate Over Three Years | |||||||
Total Revenues, 3 Yr. CAGR % | - | 25.65 | 26.27 | 11.86 | 9.35 | ||
Gross Profit, 3 Yr. CAGR % | - | 26.98 | 30.96 | 17.7 | 10.76 | ||
EBITDA, 3 Yr. CAGR % | - | -27.67 | 55.82 | 237 | 112.26 | ||
EBITA, 3 Yr. CAGR % | - | 99.22 | 64.23 | -17.55 | -24.84 | ||
EBIT, 3 Yr. CAGR % | - | 109.19 | 288.66 | -16.37 | -27.45 | ||
Earnings From Cont. Operations, 3 Yr. CAGR % | - | 152.62 | 490.37 | 62.45 | 2.43 | ||
Net Income, 3 Yr. CAGR % | - | 152.62 | 490.37 | 62.45 | 2.43 | ||
Normalized Net Income, 3 Yr. CAGR % | - | 134.53 | 179.99 | -80.34 | -13.69 | ||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | 110.41 | 484.8 | 55.56 | -7.47 | ||
Accounts Receivable, 3 Yr. CAGR % | - | 47.44 | 38.98 | 13.68 | 18.35 | ||
Inventory, 3 Yr. CAGR % | - | - | - | 26.77 | 18.52 | ||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | 55.21 | 41.35 | 21.62 | -12.18 | ||
Total Assets, 3 Yr. CAGR % | - | 51.69 | 0.77 | -1.44 | 20.06 | ||
Tangible Book Value, 3 Yr. CAGR % | - | 47.01 | 10.76 | 21.06 | 44.05 | ||
Common Equity, 3 Yr. CAGR % | - | 45.57 | 10.33 | 20.37 | 43.33 | ||
Cash From Operations, 3 Yr. CAGR % | - | 21.61 | 70.92 | 77.4 | -6.96 | ||
Capital Expenditures, 3 Yr. CAGR % | - | 44.68 | 45.26 | -51.43 | -57.4 | ||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | 47.45 | -7.93 | 4.17 | ||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | 45.18 | -6.3 | 94.64 | ||
Compound Annual Growth Rate Over Five Years | |||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | 16.32 | 18.39 | ||
Gross Profit, 5 Yr. CAGR % | - | - | - | 17.36 | 19.12 | ||
EBITDA, 5 Yr. CAGR % | - | - | - | 11.87 | 33.21 | ||
EBITA, 5 Yr. CAGR % | - | - | - | 23.37 | 88.33 | ||
EBIT, 5 Yr. CAGR % | - | - | - | 28.4 | 239.82 | ||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | 40.03 | 332.47 | ||
Net Income, 5 Yr. CAGR % | - | - | - | 40.03 | 332.47 | ||
Normalized Net Income, 5 Yr. CAGR % | - | - | - | -59.59 | 131.26 | ||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | 22.51 | 314.97 | ||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | 32.8 | 34.25 | ||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | 25.25 | 13.03 | ||
Total Assets, 5 Yr. CAGR % | - | - | - | 23.73 | 15.12 | ||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | 31.8 | 33.93 | ||
Common Equity, 5 Yr. CAGR % | - | - | - | 30.86 | 33.22 | ||
Cash From Operations, 5 Yr. CAGR % | - | - | - | -15.84 | 14.16 | ||
Capital Expenditures, 5 Yr. CAGR % | - | - | - | -24.4 | -33.62 | ||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | -14.94 | ||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | -16.49 |
- Stock Market
- Stocks
- A340450 Stock
- Financials GC Genome Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















